U
BSTC

UBS’s BioSpecifics Technologies Corp. BSTC Stock Holding History

UBS’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-825
Closed -$22K – 10942
2014
Q2 		$22K Sell
825
-2,134
-72% -$55.6K ﹤0.01% 7976
2014
Q1 		$77K Buy
+2,959
New +$70.9K ﹤0.01% 6317
2013
Q4 		– Sell
-1,874
Closed -$36K – 10926
2013
Q3 		$36K Sell
1,874
-3,225
-63% -$57.2K ﹤0.01% 7298
2013
Q2 		$80K Buy
+5,099
New +$82K ﹤0.01% 6170

Other funds holding BSTC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

UBS's BSTC Position: Q3 2014 in Review

UBS sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2014, closing a stake of 825 shares — an estimated $22K sold.

UBS first reported a position in BSTC in Q2 2013 and held it in 4 quarters. The position peaked at $80K in Q2 2013. 68 funds tracked by Wall St. Rank hold BSTC as of Q3 2014.

  • UBS reported no remaining BioSpecifics Technologies Corp. position as of Q3 2014 after selling out during the quarter.
  • UBS sold 825 BioSpecifics Technologies Corp. shares in Q3 2014, an estimated $22K.
  • UBS first reported a position in BioSpecifics Technologies Corp. in Q2 2013 and held it in 4 quarters.
  • UBS's BioSpecifics Technologies Corp. position peaked at $80K in Q2 2013.
  • 68 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.